º£½ÇÊÓƵ

Creo Medical has been boosted with simultaneous CE marking status for five new devices in the field of surgical endoscopy, in a development described by its chief executive as an “amazing milestone.”

The Chepstow-based firm, which is listed on London Alternative Investment Market, has developed new devices which form the Creo GI (gastro-intestinal) suite of advanced energy devices across four technology platforms.

The CE marking of the full range of products provides EU and º£½ÇÊÓƵ clearance.

The devices Speedboat Slim, SpydrBlade Flex, MicroBlate Fine, MicroBlate Flex and SlypSeal Flex, will be marketed at clinical practice with commercialisation expected in the second half of this year.

Creo’s chief executive Craig Gulliford said:” We are delighted to announce the CE Mark and European clearance for our wider suite of GI products. Since their first demonstration at the UEG Week Congress in October 2019 the Creo team have been gearing up for first clinical use in various markets. Procedures utilising our products have, for the right reasons, been delayed during the coronavirus pandemic as routine diagnostics have been stopped to free up resources.

“However, we are now poised with a wider range of devices than originally planned, that will allow the company to re-emerge from lock-down stronger and more confident in our medium and long-term prospects.

“It’s difficult to articulate how the whole company feels about achieving this amazing milestone. Bringing any medical device to market is very challenging especially if they are truly novel medical devices, powered by cutting edge technology.

"So, bringing five individual and game-changing devices to market at the same time is a phenomenal achievement for the entire Creo team and completes phase one of our big ambition which underpinned our IPO  [flotation] and was supported by such a great group of investors.”